These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1520030)

  • 21. [Need-adapted heparinization in hemodialysis].
    Vogel G; Kopp KF
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1563-5. PubMed ID: 1030047
    [No Abstract]   [Full Text] [Related]  

  • 22. Heparin and dialyzer membranes during hemodialysis: a literature review.
    Carbone V
    ANNA J; 1995 Oct; 22(5):452-5, 467. PubMed ID: 7487187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Readers are asked to respond on heparin prescription and administration.
    Dinwiddie LC
    Nephrol Nurs J; 2003 Feb; 30(1):81. PubMed ID: 12674957
    [No Abstract]   [Full Text] [Related]  

  • 24. Response to: Should paediatric central lines be aspirated before use?
    Evans JH
    Arch Dis Child; 2007 Oct; 92(10):937-9. PubMed ID: 17895347
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of low molecular weight heparin and standard heparin in hemodialysis.
    Bambauer R; Rücker S; Weber U; Köhler M
    ASAIO Trans; 1990; 36(3):M646-9. PubMed ID: 2174689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Heparin-free hemodialysis in chronic patients for temporary management of conditions with a high risk of bleeding].
    Stradtmann H; Förster S; Jalinski W
    Z Urol Nephrol; 1988 Jul; 81(7):449-53. PubMed ID: 3176720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parameters of hemostasis during treatments associating fractionated heparin administered subcutaneously to standard and fractionated heparin administered intravenously in the chronic hemodialysis patient].
    Morinière P; Diéval J; Roussel B; Gross S; Bayrou B; Delobel J; Fournier A
    Nephrologie; 1990; 11(3):141-6. PubMed ID: 2234270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin.
    Maurin N; Ballmann M
    Clin Nephrol; 1988 Jul; 30(1):35-41. PubMed ID: 3061692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional vs "tight" heparinization in hemodialysis.
    Lee JH; Cocke TB; Gonzalez FM
    Proc Clin Dial Transplant Forum; 1974; (4):239-47. PubMed ID: 4549633
    [No Abstract]   [Full Text] [Related]  

  • 30. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
    Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
    Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis.
    Ryan KE; Lane DA; Flynn A; Shepperd J; Ireland HA; Curtis JR
    Thromb Haemost; 1991 Sep; 66(3):277-82. PubMed ID: 1745997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematic modeling of dialysis therapy.
    Sargent JA; Gotch FA
    Kidney Int Suppl; 1980 Sep; 10():S2-10. PubMed ID: 6777577
    [No Abstract]   [Full Text] [Related]  

  • 33. WBPTT and ACT clotting time methods for use in hemodialysis.
    Anderson R; Steeno M
    AANNT J; 1982 Apr; 9(2):27-30. PubMed ID: 6917761
    [No Abstract]   [Full Text] [Related]  

  • 34. A low molecular heparin fraction as an anticoagulant during hemodialysis.
    Ljungberg B
    Clin Nephrol; 1985 Jul; 24(1):15-20. PubMed ID: 4017295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.
    Lee KB; Kim B; Lee YH; Yoon SJ; Kang WH; Huh W; Kim DJ; Oh HY; Kim YG
    Nephron Clin Pract; 2004; 97(1):c5-10. PubMed ID: 15153761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
    Low CL; Bailie G; Morgan S; Eisele G
    Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of heparin locking frequency on preventing temporary dialysis catheter dysfunction in haemodialysis patients.
    Oran NT; Eser I
    J Ren Care; 2008 Dec; 34(4):199-202. PubMed ID: 19090898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of prostacyclin in regular dialysis therapy.
    Turney JH; Williams LC; Fewell MR; Parsons V; Weston MJ
    Proc Eur Dial Transplant Assoc; 1980; 17():318-22. PubMed ID: 7017677
    [No Abstract]   [Full Text] [Related]  

  • 39. Loss of catheter lock fluid is caused by hydraulic effects and not by diffusion.
    Polaschegg HD
    Blood Purif; 2009; 28(3):226. PubMed ID: 19684387
    [No Abstract]   [Full Text] [Related]  

  • 40. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR
    Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.